New Clinical Trial for Alveolar Soft Part Sarcoma in the United Kingdom: CASPS – A Phase II Trial of Cediranib
Dear ASPS Community, We are very happy to report the opening of another clinical trial for ASPS patients in the United Kingdom. This new clinical trial is a phase II trial of Cediranib. Every trial brings with it the hope for cure! ASPS patients who are trying Cediranib are sharing their experience on iCureASPS Forum. […]
Support Research of ASPS: A Novel Mouse Tumor Model
In collaboration with iCureASPS, Dr. George Demetri, Dr. Massimo Loda, and Dr. Ewa Sicinska at the Dana Farber Cancer Institute in Boston have started a new initiative that aims to find an effective therapy for Alveolar Soft Part Sarcoma. This research will make use of a cell line that was established from a tumor taken […]
The Third Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ)
The third annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ) took place in May. This year, over $12,000 was raised and donated directly to the laboratory of Dr. Glenn Dranoff at the Dana Farber Cancer Institute in Boston to support his efforts in finding a cure for Alveolar Soft Part Sarcoma. […]
NIH study finds Cediranib benefits patients with ASPS
An experimental drug, cediranib, may benefit alveolar soft part sarcoma (ASPS) patients, according a recent clinical trial. The trial, carried out by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, showed that tumors shrank in more than 50 percent of ASPS patients who were treated with cediranib. These findings […]
Register Now to Join Team ASPS in the 2011 PMC Bike Ride
Since its inception, the iCureASPS organization has transferred more than a quarter million dollars to keep up research, and clinical trials that aim to find a cure for ASPS. I would like to thank the ASPS community, friends, and family who are supporting us in our goal of finding a cure for ASPS. Please make […]
PMC 2010 Fund Raiser
Dear ASPS Community! This coming weekend in August 2010, Team ASPS will ride in the Pan-Massachusetts Challenge (PMC) for the 7th time! The PMC is a bike-a-thon that crosses Massachusetts to raise money for cancer research and clinical trials at the Dana-Farber Cancer Institute in Boston. I am asking you to sponsor our team bike […]
Event Summary: The second Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ)
The second Annual Knockin’ Down ASPS Event in the memory of Anthony Salisbury (AJ) took place on April 10th, 2010. Over $16,000 were raised this year, which were donated directly to the laboratory of Dr. Glenn Dranoff at the Dana Farber Cancer Institute in Boston in favor of his efforts of finding a cure for […]
Minimally Invasive Procedures for Tumor Ablation
For Alveolar Soft Part Sarcoms patients the use of aggressive surgery, appropriate diagnostic imaging, and long-term surveillance for metastases are critical to achieve long-term survival (Kayton et al 2006). When surgery is not possible, then local treatment like tumor ablation may be considered. In the past we discussed the benefits of Stereotactic Radiosurgery (SRS). There are different […]
Potential Therapeutic Targets in Alveolar Soft Part Sarcoma – by Dr. Dina Lev
Dr. Dina Lev, from the Cancer Biology and the Sarcoma Research Center at the University of Texas M. D. Anderson has published a new study on Alveolar Soft Part Sarcoma. Her study appeared in the Journal of Histopathology. The aim of this study was to evaluate the expression of potential gene therapeutic targets in a cohort of […]
Cediranib (AZD2171): Phase II Study in Patients With Alveolar Soft Part Sarcoma
Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the drug inhibits angiogenesis: the formation of new blood vessels. Angiogenesis, in the context of cancer, enables blood supply to tumors, resulting in tumor growth and spread. Cediranib is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral […]